Single-center Open Randomized Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim (JSC "BIOCAD", Russia) Compared to Neupogen (F. Hoffman-La Roche Ltd., Switzerland)
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Filgrastim (Primary) ; Filgrastim (Primary)
- Indications Diabetic neuropathies; Leucocytosis; Neutropenia
- Focus Pharmacokinetics
- Sponsors Biocad
- 17 Dec 2018 Status changed from not yet recruiting to completed.
- 09 May 2016 New trial record